
Justice Department files appeal to keep age restrictions in place for emergency contraceptives
The U.S. Department of Justice filed a notice on May 1 to appeal New York Judge Edward R. Korman’s decision last month to make levonorgestrel-based emergency contraceptives available without a prescription and without point-of-sale or age restrictions.
The U.S. Department of Justice filed a notice on May 1 to appeal New York Judge Edward R. Korman’s decision last month to make levonorgestrel-based emergency contraceptives available without a prescription and without point-of-sale or age restrictions.
On April 5,
In his ruling, Judge Korman said that the decisions made by the secretary of the U.S. Department of Health and Human Services with respect to Plan B One-Step and by the FDA to deny the Citizen Petition with respect to availability of emergency contraceptives to patients of any age without a prescription “were arbitrary, capricious, and unreasonable.”
In its letter to Judge Korman yesterday, the Justice Department says that it is not in the public interest to have drugs reclassified as non-prescription by a court order, and it is the FDA that must make those decisions.
Two days ago, FDA did change the age and point-of-sale restrictions for one of the levonorgestrel-based emergency contraceptives,
Nancy Northup, president and CEO of the Center for Reproductive Rights, said her organization was disappointed with the Obama and Bush administrations for their actions on denying access to obtain emergency contraceptives for women of all ages. The Center for Reproductive Rights was one of the original groups to file the
“Women who urgently need emergency contraception have been delayed in getting it or denied access for more than a decade because of political maneuverings of the last two presidential administrations,” Northup said in a May 1 press statement. “The federal court [New York Judge Korman] has made clear that these stalling tactics were based purely on politics, not science.”
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.


























































































































































